ClinicalTrials.gg
CompletedNCT04580797Updated Mar 8, 2021

Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations

A Phase 1 interventional study of PF-06700841 IR and PF-06700841 MR1 in Healthy Participants, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-08.

Sponsored by Pfizer · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jan 2021, 5 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of PF-06700841 following single and multiple oral doses as modified release (MR) formulations in healthy, adult participants under fasted and fed conditions. The objective of Part A is to evaluate the relative bioavailability and food effect of 2 new MR formulations, MR1 and MR2. The objective of Part B is to evaluate the PK and safety/tolerability of MR3 formulation following multiple dose administration over a 7-day period. Overall, results from both parts will facilitate further development of an MR formulation for future clinical studies.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants between 18 -55 years of age.
  • of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
  • Participants who are willing and able to comply with all scheduled visits, treatment
  • plan, laboratory tests, lifestyle considerations, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Conditions that affect drug absorption (e.g., gastrectomy cholecystectomy)
  • History of venous and arterial thrombosis (ie, deep venous thrombosis, pulmonary embolism) or hereditary clotting disorders (in first degree immediate relatives)
  • Positive urine drug test.
  • History of (HIV) infection, , or ; positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed.
  • History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    PF-06700841: IR, MR1, MR2, MR1_fed

    Participants receive single doses of immediate release (IR) followed by modified release (MR) MR1 and MR2, all in fasted condition followed by MR1 in fed condition in Periods 1-4

    Drug: PF-06700841 IR · Drug: PF-06700841 MR1 · Drug: PF-06700841 MR2

  • Experimental
    PF-06700841: MR1, MR2, IR, MR1_fed

    Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR1 in fed condition in Periods 1-4

    Drug: PF-06700841 IR · Drug: PF-06700841 MR1 · Drug: PF-06700841 MR2

  • Experimental
    PF-06700841: MR2, IR, MR1, MR1_fed

    Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR1 in fed condition in Periods 1-4

    Drug: PF-06700841 IR · Drug: PF-06700841 MR1 · Drug: PF-06700841 MR2

  • Experimental
    PF-06700841: IR, MR1, MR2, MR2_fed

    Participants receive single doses of IR followed by MR1 and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4

    Drug: PF-06700841 IR · Drug: PF-06700841 MR1 · Drug: PF-06700841 MR2

  • Experimental
    PF-06700841: MR1, MR2, IR, MR2_fed

    Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR2 in fed condition in Periods 1-4

    Drug: PF-06700841 IR · Drug: PF-06700841 MR1 · Drug: PF-06700841 MR2

  • Experimental
    PF-06700841: MR2, IR, MR1, MR2_fed

    Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4

    Drug: PF-06700841 IR · Drug: PF-06700841 MR1 · Drug: PF-06700841 MR2

  • Experimental
    PF-06700841 MR3 (Dose A) or matching placebo

    Participants receive dosing regimen 1 of MR3 (Dose A) or matching placebo for 7 days under fasted condition

    Drug: PF-06700841 MR3 · Other: Placebo

  • Experimental
    PF-06700841 MR3 (Dose B) or matching placebo

    Participants receive dosing regimen 1 of MR3 (Dose B) or matching placebo for 7 days under fasted condition

    Drug: PF-06700841 MR3 · Other: Placebo

  • Experimental
    PF-06700841 MR3 (Dose C) or matching placebo

    Participants receive dosing regimen 1 of MR3 (Dose C) or matching placebo for 7 days under fasted condition

    Drug: PF-06700841 MR3 · Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of PF-06700841 in Part A

    Time frame: pre-dose, 1,2,4,6,8,10,12,16,24,36,48,72 hours post dose

  2. Area under the plasma concentration-time curve from time zero to the last measured concentration (AUClast) of PF-06700841 in Part A

    Time frame: pre-dose, 1,2,4,6,8,10,12,16,24,36,48,72 hours post dose

  3. Area under the plasma concentration-time curve from time zero to extrapolated infinite time (AUCinf) of PF-06700841 if data permit in Part A

    Time frame: pre-dose, 1,2,4,6,8,10,12,16,24,36,48,72 hours post dose

  4. Time to reach maximum observed plasma concentration (Tmax) of PF-06700841 in Part A

    Time frame: pre-dose, 1,2,4,6,8,10,12,16,24,36,48,72 hours post dose

  5. Number of participants with Treatment- Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation due to AEs in Part B

    Time frame: Baseline to Day 10

Secondary outcomes

  1. Number of subjects with clinically relevant changes in Electrocardiogram (ECG) parameters in Part A

    Time frame: Pre-dose and 96 hours post dose

  2. Number of subjects with clinically relevant changes in vital signs in Part A

    Time frame: Pre-dose and 96 hours post dose

  3. Number of participants with clinically relevant changes in clinical laboratory tests in Part A

    Time frame: Baseline and 96 hours post dose

  4. Number of participants with Treatment- Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation due to AEs in Part A

    Time frame: Baseline to Day 4

  5. Maximum Observed Plasma Concentration (Cmax) of PF-06700841 in Part B on Day 1

    Time frame: pre-dose, 1,2,3,4,6,8,10,12,16 hours post dose on Day 1

  6. Time to reach maximum observed plasma concentration (Tmax) of PF-06700841 in Part B on Day 1

    Time frame: pre-dose, 1,2,4,6,8,10,12,16 hours post dose on Day 1

  7. Maximum Observed Plasma Concentration (Cmax) of PF-06700841 in Part B on Day 7

    Time frame: pre-dose on Day 7, 1,2,3 4,6,8,12,16,24,48,72 hours post dose on Day 7

  8. Time to reach maximum observed plasma concentration (Tmax) of PF-06700841 in Part B on Day 7

    Time frame: pre-dose on Day 7, 1,2,3 4,6,8,12,16,24,48,72 hours post dose on Day 7

  9. Area under the plasma concentration-time curve from time zero to 24 hours (AUC24) of PF-06700841 in Part B on Day 1

    Time frame: pre-dose, 1,2,4,6,8,10,12,16 hours post dose on Day 1, pre-dose on Day 3 and Day 5, pre-dose on Day 7, 1,2,3,4,6,8,12,16,24,48,72 hours post dose on Day 7

  10. Area under the plasma concentration-time curve from time zero to 24 hours (AUCtau) of PF-06700841 in Part B on Day 7

    Time frame: pre-dose, 1,2,4,6,8,10,12,16 hours post dose on Day 1, pre-dose on Day 3 and Day 5, pre-dose on Day 7, 1,2,3,4,6,8,12,16,24,48,72 hours post dose on Day 7

  11. Terminal half-life of PF-06700841 in Part B

    Time frame: pre-dose, 1,2,4,6,8,10,12,16 hours post dose on Day 1, pre-dose on Day 3 and Day 5, pre-dose on Day 7, 1,2,3,4,6,8,12,16,24,48,72 hours post dose on Day 7

07

Study locations

2 sites
  • Quotient Sciences
    Coral Gables, Florida 33134, United States
  • Quotient Sciences-Miami
    Miami, Florida 33126, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Jan 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2020
First posted
Oct 8, 2020
StartActual
Oct 2, 2020
Primary completionActual
Jan 11, 2021
CompletionActual
Jan 11, 2021
Last update
Mar 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04580797
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Oct 2, 2020
Primary completion
Jan 11, 2021
Completion
Jan 11, 2021
Last update
Mar 8, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06700841

Start the discussion